Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 789-795

  Wallace, Carol A ^a,d   Ravelli, Angelo ^b   Huang, Bin ^c   Giannini, Edward H ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Juvenile idiopathic arthritis; Remission criteria; Validation

Indexed keywords

RHEUMATOID FACTOR;

ARTHRITIS; ARTICLE; CONSENSUS; DISEASE COURSE; EXERCISE; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; OUTCOME MEASURES IN RHEUMATOID ARTHRITIS CLINICAL TRIALS; POLYARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY;

ARTHRITIS, JUVENILE RHEUMATOID; DELPHI TECHNIQUE; DISCRIMINANT ANALYSIS; FEASIBILITY STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 33645833004     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
2. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
3. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 2003;62 Suppl 2:ii2-9.
4. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
5. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
6. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
7. Kalden JR, Smolen JS, Emery P, et al. Leflunomide in combination therapy. J Rheumatol 2004;31 Suppl 71:25-30.
8. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
9. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with inflixiniab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence ot synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
10. US Food and Drug Administration. Guidance for industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. Washington, DC: US Government Printing Office: 1999.
11. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003;30:579-84.
12. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
13. Flato B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
14. Wallace CA, Rupeno N, Giannini EH, for the CARRA, PRINTO and PRCSG. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
15. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
16. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982;9:758-62.
17. Delbeeq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning. A guide to nominal group and delphi processes. Middleton. WI: Green Briar Press; 1986.
18. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton. 2001. J Rheumatol 2004;31:390-2.
19. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
20. Bellamy N. Clinimetric concepts in outcome assessment: the OMERACT filter. J Rheumatol 1999;26:948-50.
21. Guzman J, Burgos-Vargas R, Duarte-Salazar C, Gomez-Mora P. Reliability of the articular examination in children with juvenile rheumatoid arthritis: interobserver agreement and sources of disagreement. J Rheumatol 1995;22:2331-6.
22. Senocak O, Unsal E, Akalin E, Ergor G. Interobserver reliability of articular examination in juvenile idiopathic arthritis. Turk J Pediatr 2003;45:29-32.
23. Ortiz Z, Shea B, Garcia Dieguez M, et al. The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. J Rheumatol 1999;26:210-6.
24. Molenaar LT, Boers M, van der Heijde DM, et al. Imaging in rheumatoid arthritis: results of group discussions. J Rheumatol 1999;26:749-51.
25. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
26. Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046-55.
27. Boers M, van der Heijde DM. Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs. Drugs 2002;62:1717-24.
28. Lassere MN, Bird P. Measurements of rheumatoid arthritis disease activity and damage using magnetic resonance imaging. Truth and discrimination: does MRI make the grade? J Rheumatol 2001;28:1151-7.
29. McQueen F, Lassere M, Edmonds J, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol 2003;30:1387-92.
30. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.